Antilipemic Agents - Pharmacology
Research News and Information

Monday, November 23, 2009

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.

Nov 2009 OBJECTIVES: Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function. BACKGROUND: NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density ... Read more...

Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats.

29 Sep 2009 Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are widely used as sensitive markers of possible tissue damage, particularly liver toxicity. Lipid-lowering drugs, such as fibrates, slightly increase serum ... Read more...

Probing the fibrate binding specificity of rat liver fatty acid binding protein.

8 Sep 2009 Liver-fatty acid binding protein (L-FABP) is found in high levels in enterocytes and is involved in cytosolic solubilization of fatty acids. In addition, L-FABP has been shown to bind endogenous and exogenous lipophilic compounds, suggesting that it ... Read more...

Latest indexed articles for 'Antilipemic Agents - Pharmacology'

These are the very latest articles for this heading:

• Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging. Nov 2009
• Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. Nov 2009
• Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. 29 Sep 2009
• Probing the fibrate binding specificity of rat liver fatty acid binding protein. 8 Sep 2009
• Ethyl-eicosapentaenoic acid reduces liver lipids and lowers plasma levels of lipids in mice fed a high-fat diet. 30 Aug 2009
• Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. 30 Aug 2009
• Antidiabetic and antilipidemic effect of eremanthin from Costus speciosus (Koen.)Sm., in STZ-induced diabetic rats. 16 Aug 2009
• The hypolipidemic effect of an ethyl ester of algal-docosahexaenoic acid in rats fed a high-fructose diet. 3 Aug 2009
• Effects of sour tea (Hibiscus sabdariffa) on lipid profile and lipoproteins in patients with type II diabetes. 30 Jul 2009
• Antiatherogenic activity of Dendropanax morbifera essential oil in rats. 30 Jul 2009
• Antihyperlipidemic compounds from the fruit of Piper longum L. 30 Jul 2009
• Lipid management in clinical practice. 30 Jul 2009
• Current medical aspects of pantethine. 28 Jul 2009
• Carotid atherosclerosis progression and ACAT inhibition. 13 Jul 2009
• Carotid atherosclerosis progression and ACAT inhibition. 13 Jul 2009
• Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. 8 Jul 2009
• Antihyperglycemic, antihyperlipidemic and antioxidant effects of Dihar, a polyherbal ayurvedic formulation in streptozotocin induced diabetic rats. 29 Jun 2009
• Supplementation with magnesium and vitamin E were more effective than magnesium alone to decrease plasma lipids and blood viscosity in diabetic rats. 29 Jun 2009
• [PCSK9 - break through in the prevention and treatment of arteriosclerosis?] 29 Jun 2009
• Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. 29 Jun 2009

See a longer list of these articles.

Technical information about 'Antilipemic Agents'

Definition: Substances used to treat HYPERLIPIDEMIAS.

Registry Number: 0

Descriptor UI: D000960

Alternative terms: Antilipemic Agents; Agents, Antilipemic; Antihyperlipidemics; Antihyperlipemics; Antilipemics; Antilipemic Drugs; Drugs, Antilipemic; Hypolipidemic Agents; Agents, Hypolipidemic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.186.071; D27.505.954.230;

History Note: 72(66)